Shots:
- The US FDA has granted IND clearance to ATI-052 for the initiation of P-Ia/Ib trial
- The P-Ia/Ib trial assessing single & multiple ascending doses of ATI-052 followed by PoC portion in an undisclosed indication, is expected to begin in Q2’25
- ATI-052 blocks upstream TSLP receptor signaling & downstream IL-4/IL-13 activation to inhibit a central proinflammatory pathway
Ref: Aclaris Therapeutics | Image: Aclaris Therapeutics
Related News:- Merck’s Keytruda Regimen Receives Health Canada’s Approval for Malignant Pleural Mesothelioma (MPM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
